Boston Scientific Updates Instructions for Cryoablation Balloons After Reports Of Severe Injuries
BSXBoston Scientific updates Polarx catheter guidelines due to atrio-esophageal fistula risks, highlighting safer usage practices after FDA approval.
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
BSXKey Takeaways From Boston Scientific Analyst Ratings
BSXWhy Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
BSXBoston Scientific's latest trial shows safety and efficacy endpoints for stroke prevention in atrial fibrillation patients.
Needham Reiterates Hold on Boston Scientific
BSXReported Saturday, Boston Scientific's WATCHMAN FLX Device Shows Superior Bleeding Risk Reduction Compared To Oral Anticoagulants After Cardiac Ablation In OPTION Clinical Trial
BSXBoston Scientific Has Agreed To Acquire Cortex, An Ajax Health Company, Specific Deal Terms Were Not Disclosed
BSXNeedham Reiterates Hold on Boston Scientific
BSXCitigroup Maintains Buy on Boston Scientific, Raises Price Target to $87
BSXIf You Invested $100 In This Stock 10 Years Ago, You Would Have $600 Today
BSXReported Saturday, MODULAR ATP Study Of Boston Scientific's mCRM System Meets Safety And Efficacy Endpoints
BSXWhere Boston Scientific Stands With Analysts
BSXAnalysts have provided the following ratings for Boston Scientific (NYSE:BSX) within the last quarter:
Piper Sandler Maintains Overweight on Boston Scientific, Raises Price Target to $50
BSXBoston Scientific Receives FDA Clearance For EMBOLD Fibered Detachable Coil
BSX5 Analysts Have This to Say About Boston Scientific
BSXBoston Scientific (NYSE:BSX) has observed the following analyst ratings within the last quarter:
Raymond James Maintains Strong Buy on Boston Scientific, Raises Price Target to $50
BSXSVB Leerink Maintains Market Perform on Boston Scientific, Raises Price Target to $48
BSX